Welcome to Team Australian @MedTech Conference 2025 San Diego

Australia is a great partner to develop your medtech innovations, offering a robust and growing environment for medical device development, supported by strong intellectual property protections, a skilled workforce, a well-regarded regulatory system, and government investment in innovation. Australia operates a world-famous Clinical Trial Notification (CTN) scheme allowing faster start-up of clinical trials, and clinical trials in Australia can be around 60 per cent cheaper than comparable clinical trials in the US. Team Australia hopes to connect with you to discuss these advantages and future collaborations and partnerships.

10 Results found

Top Professional services in MTP MedTech 2025

All Categories

The Australian Trade and Investment Commission (Austrade) is Australia’s leading trade promotion and investment attraction agency.

Trade Offices

Contact person(s):

No of Employees: 1-1,200

Corcillum is a diagnostics and digital health company redefining coronary care and research with corSUITE™, an image annotation and multi-physics modelling platform. Using patented algorithms, the coronary physiology module corFLUX™ calculates key metrics, such as virtual FFR, plus a portfolio of up to 50 novel metrics used for the early identification of vessel and plaque instability, independent of plaque morphology or ischemia, that may lead to future acute events. Our mission is to prevent one million AMI’s by 2050; with corSUITE and corFLUX we aim to empower clinicians in the cath lab and radiology suite to improve triage and personalise treatment, while empowering researchers and CROs with a powerful data and digital twin platform built for the AI and high-performance computing era.

Working with:

Contact person(s):

Languages

English

Exa is an award-winning product development consultancy specializing in the design, engineering, and commercialization of medical technologies. We support startups through to multinationals on FDA Class I–III devices, working within ISO 13485, ISO 14971, IEC 62304, and IEC 60601 standards to take products from concept to manufacture.As a Certified B Corporation, we pair people-first values with deep technical expertise to deliver safe, sustainable, and commercially focused MedTech solutions.

Emerging Medtech

Working with:

Contact person(s):

Year founded: 2017

Global Victoria is an agency of the Victorian Government.

Innovate MedtechInnovate Medtech is a global Medtech advisory and product development company dedicated to creating the medical devices of the future. We are a one-stop shop for Medtech startups, providing a founder-friendly service shaped by real experience. Having built Medtech companies ourselves, we understand the challenges of the journey and are there with you every step of the way.We combine engineering, science, intellectual property and business expertise to deliver commercially ready solutions. Acting as an extension of your team, our senior global experts bring more than 150 years of combined experience across engineering, science, regulatory affairs, IP and manufacturing.Our Services• Rapid prototyping and proof-of-concept development• Design and development support through V&V and manufacturing• Scientific support for preclinical study design and animal ethics• IP advisory and competitive landscape analysis• Quality and regulatory support (TGA, FDA, ISO 13485)• Grant writing and R&D tax incentive access• Capital raise support, including pitch decks, investor diligence and deal room preparationOur patent-literate engineers and scientists apply the scientific method to engineering, ensuring the right solution meets the right problem. We focus exclusively on Medtech and health-tech, helping turn ideas into real-world products.

Emerging Medtech

Working with:

Contact person(s):

Year founded: 2024

No of Employees: 5-20

Invetech is a full-service provider of product design, instrument development, and contract manufacturing with a focus on healthcare markets. With over 30 years of experience, Invetech accelerates the commercialization of breakthrough diagnostics and c...

Mobius Medical is a Contract Research Organization (CRO) providing a turnkey solution, end-to-end service, for the management of clinical trials. Our focus is on medical device clinical trials and specifically Class II, III and active implantable medical devices. Our key focus is designing and implementing a clinical strategy specific to our clients' needs and their investigational product. Mobius conducts clinical trials in the United States, Australia and New Zealand.Australia has long been a destination for US companies wanting to conduct Early Feasibility Studies (EFS). With an expedited regulatory pathway taking 1-2 days to obtain approval, IRB approvals in 12 weeks, and a very competitive R&D tax incentive, US companies can obtain EFS data quickly to support IDE applications. With offices in Australia and the US, Mobius can seamlessly jump from a single center EFS study in Australia, to multicenter Pivotal studies incorporating sites across the US and Australia. At Mobius we focus on strategically design studies to expedite commercialization.

Working with:

Contact person(s):

Year founded: 2008

No of Employees: 25-35

Molecule2Market (M2M) is a boutique, full-service Contract Research Organisation (CRO) with deep expertise in designing and delivering medical device clinical trials alongside pharmaceutical and diagnostic studies. Our team understands the unique scientific, regulatory, and operational challenges facing MedTech innovators, from first-in-human feasibility studies through to pivotal trials required for market approval.With an average of over 20 years’ experience, our senior team members bring hands-on knowledge of both ISO 14155 standards and regional regulatory requirements, ensuring trials are conducted to the highest quality and compliance standards. We have successfully managed device trials across multiple therapeutic areas, including endocrinology, cardiology, surgical, ophthalmological, diagnostics, and digital health technologies.M2M’s footprint spans all major cities of Australia, and New Zealand and the USA, allowing us to run efficient, multicentre studies that access diverse patient populations. Australia, in particular, offers significant advantages for device development, including streamlined ethics/regulatory pathways, generous R&D incentives, and internationally recognised data accepted by the FDA and EMA.As a boutique CRO, we pride ourselves on our agility, responsiveness, and personal approach. Each team member is carefully chosen not only for their technical expertise but also for their ability to collaborate closely with sponsors, investigators, and sites — creating strong partnerships that accelerate study delivery.M2M is also a proud member of AICROS (the Association of International Contract Research Organizations), an alliance of well-established, regionally based CROs working together to provide high-quality clinical research services on a global scale. Through this network, we can seamlessly extend support to Europe, Asia, and beyond, giving MedTech companies a single, trusted partner for global development programs.Whether you are running an early feasibility device study, a large-scale pivotal trial, or seeking guidance on operational strategy, M2M brings the right blend of scientific insight, operational rigour, and global reach to support your success.

Contact person(s):

Languages

English

Year founded: 2012

No of Employees: 17-22

MTPConnect is Australia's Life Sciences Innovation Accelerator – an independent, not-for-profit organisation established by the Australian Government to champion the continuing growth of Australia's vibrant medical products sector.MTPConnect’s focus is taking cutting-edge research from bench to bedside by working collaboratively with all parts of Australia’s medical technology, biotechnology and pharmaceutical sector; from universities and medical research institutes to start-ups and small to medium sized enterprises to listed companies, and governments, policy makers and regulators.MTPConnect designs and delivers accelerator, sector building and workforce programs for Australian Government agencies and state governments. It co-funds cutting edge innovation and research projects, supports expansion of the clinical trials ecosystem, develops workforce commercialisation skills and represents the Australian sector with a strong and independent voice to promote connections to international markets and improve access to global supply chains. MTPConnect operates the industry-led Australian Antimicrobial Resistance Network – AAMRNet – a collaborative network of key stakeholders working together to address the impact of AMR on human health. It seeks to create an accelerator that will back Australian research into new antimicrobial innovations and to secure investment for a pilot subscription fund for novel antimicrobials to ensure Australians have equitable access to the latest life-saving antibiotics. It also has a dedicated Health and Biosecurity team driving development of dual purpose, advanced medical countermeasures and Defence/National Security related technologies.Across MTPConnect’s accelerator programs, more than $152 million has been directly injected into the Australian life sciences sector, supporting nearly 200 innovation projects. Its investments have leveraged more than $1.3 billion in additional industry contributions and flow-on external investment, allowing SMEs to scale-up and create new jobs and new medical products.MTPConnect’s work has seen more than 1,696 new technologies invented or progressed, 374 new products launched and over 746,000 patients treated.

Trade Offices

Contact person(s):

Year founded: 2015

PeriCoach America is a medtech company with flagship women's health system, PeriCoach. PeriCoach is an evidence-backed digital health system developed in Australia to help women strengthen their pelvic floor muscles and manage urinary incontinence. FDA-cleared, CE-marked, and ARTG-listed, PeriCoach offers a non-invasive, clinically validated alternative to surgery or medication. PeriCoach is being commercialised in the US and is also available in Australia.

Emerging Medtech

Contact person(s):

Year founded: 2023

View all Companies